NIH recommends Allergan’s Truberzi as 1st ever treatment for IBS-D & more —3 GI company key notes

Here are three updates on GI companies from the past week:

Advertisement

The National Institute for Health and Care Excellence recommended Allergan’s Truberzi for irritable bowel syndrome with diarrhea, making it the first such treatment to be recommended for use by the agency.

Takeda CEO Christophe Weber reaffirmed the company’s commitment to globalizing its brand and products amid struggling fiscal year 2017 sales.

Commonwealth Diagnostics relaunched its U.S.-based gastroenterology diagnostic testing business.

More article on gastroenterology: 
Stock market week-in-review for 5 large GI companies — Aug. 28-Sept. 1
GI leader to know: Dr. Mark Cossentino of Endoscopy Center of El Paso
GI center to know: Endoscopy Center of El Paso

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.